Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

47.21 +0.07 (+0.15%)
Official Closing Price Updated: 7:00 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
78 79 Next >
Bristol-Myers Squibb Shares Rise After Analyst Upgrades, Positive Pipeline Outlook
Bristol-Myers Squibb Inc. (NYSE: BMY) shares saw are trading higher Monday. Jefferies analyst, Akash Tewari, raised his rating on the stock from Hold to Buy and increased the price target from $63 to... 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
Is Bristol-Myers Squibb Stock a Millionaire Maker?
Via The Motley Fool
Where Will Bristol Myers Squibb Be in 5 Years?
Via The Motley Fool
Is Bristol Myers Squibb Stock a Buy?
Via The Motley Fool
Bristol Myers Squibb Announces Dividend Increase
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
From Bristol Myers Squibb
Via Business Wire
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
 
Via Benzinga
Why Is Purple Biotech Stock Trading Higher On Monday?
Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed improved survival rates, biomarker responses, and disease control outcomes. 
Via Benzinga
Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program
Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach. 
Via Benzinga
Topics Lawsuit
3 Magnificent S&P 500 Dividend Stocks Down 27%, 28%, and 29% to Buy and Hold Forever
The sell-offs of these stocks were driven by issues that were never going to last. 
Via The Motley Fool
Topics Stocks
Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like. 
Via Investor's Business Daily
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Via The Motley Fool
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
From Bristol Myers Squibb
Via Business Wire
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases. 
Via Benzinga
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 16
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Nov. 11-15, 2024. 
Via Talk Markets
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent value rights holders' payments. 
Via Benzinga
Topics Lawsuit
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
From Bristol Myers Squibb
Via Business Wire
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends. 
Via The Motley Fool
2 Beaten-Down Dividend Stocks to Buy and Hold
They're down, but they aren't out, at least not in the eyes of patient investors. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans. 
Via Benzinga
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb. 
Via Investor's Business Daily
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture. Let’s take a closer look at the transactions for those interested in trading like the insiders. 
Via Talk Markets
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.